MSD vaccines will be sold by Boryung·Kwangdong

HK Inno.N withdraws its vaccine business worth KRW 200 bil

Boryung Biopharma to sell Zostavax, Vaxneuvance, Prodiax, RotaTeq

Kwangdong to sell Gardasil, Gardasil 9… sales of Vaqta, MMR2 will be reviewed separately

HK Inno.N virtually withdraws from the vaccine business in 2 yrs… business worth KRW 200 bil

The domestic sales rights for 8 types of MSD vaccines have changed hands recently.

 

Although HK Inno.N was in charge of joint sales for MSD vaccines in Korea, the vaccines will be separately sold by Boryung Biopharma and Kwangdong Pharmaceutical each.

 

After signing a copromotion agreement with MSD for its vaccines at the end of 2021, HK Inno.N began joint sales last year.

 

However, with this transfer of sales rights, the company is effectively withdrawing from the vaccine business after 2 years.

 

According to industry sources on the 23rd, MSD’s partner in joint sales and distribution of its 8 vaccines will be changed from HK Inno.N to Boryung Biopharma and Kwangdong Pharmaceutical starting next year.

 

The companies recently signed a copromotion contract for this purpose.

 

Boryung Biopharma will sell the shingles vaccine ‘Zostavax,’ the pneumococcal vaccine ‘Prodiax 23,’ the rotavirus vaccine ‘RotaTeq,’ and MSD’s new pneumococcal vaccine ‘Vaxneuvance.’ Vaxneuvance Is a 15-valent pneumococcal conjugate vaccine, which gained attention as the first pneumococcal vaccine to be authorized in Korea in 13 years.

 

Kwangdong Pharmaceutical will sell the HPV vaccines ‘Gardasil,’ and ‘Gardasil 9.’ The copromotion partners for the hepatitis A vaccine ‘Vaqta’ and the measles/mumps/rubella vaccine 'MMR2' have not been determined yet.

 

The pharmaceutical industry predicts that it is highly likely that MSD will sign an agreement with a third party other than Boryung Biopharma and Kwangdong Pharmaceutical for the two vaccines.

 

On this, an MSD official said, “We have signed a new copromotion agreement for Zostavax, Prodiax 23, Vaxneuvance, RotaTeq, Gardasil, and Gardasil 9.

 

But we are separately reviewing sales for Vaqta, MMR2.” Seven of MSD’s vaccines other than the Vaxneuvance that was recently approved had been sold by HK Inno.N until now.

 

HK Inno.N signed a copromotion and distribution agreement with MSD Korea in November 2021.

 

With the transfer, HK Inno.N is effectively withdrawing from the vaccine business after two years.

 

Analysis suggests that a gap worth KRW 200 billion in annual sales will be inevitable during this process.

 

According to the market research institution IQVIA, last year's sales of the 7 vaccines in discussion amounted to KRW 204.9 billion.

 

Compared to the KRW 150.4 billion they had posted in 2021 before HK InnoN took over copromotion, sales increased by 36% in a single year.

 

This year, it recorded cumulative sales of KRW 146.2 billion by Q3.

 

If this trend continues, the vaccines are expected to record sales of around KRW 200 billion, similar to last year.